ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 237,49
0,61%
Dow Jones
39 387,76
0,85%
DAX
18 810,09
0,70%
Brent Oil
83,895
-0,07%
Bitcoin
62 958,88
-0,14%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) Actualités

ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ANTX
DateHeureSourceTitreSymboleSociété
28/03/202421h10Business WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
13/02/202423h11Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202412h45Business WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
30/01/202422h10Business WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
19/01/202400h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
02/01/202422h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h05Business WireAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
06/11/202313h00Business WireAN2 Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
18/10/202313h00Business WireAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
11/10/202306h01Business WireAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023NASDAQ:ANTXAN2 Therapeutics Inc
26/09/202313h00Business WireAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
13/09/202313h00Business WireAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
16/08/202322h50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANTXAN2 Therapeutics Inc
16/08/202304h42Business WireAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common StockNASDAQ:ANTXAN2 Therapeutics Inc
10/08/202322h10Business WireAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
09/06/202322h14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANTXAN2 Therapeutics Inc
25/05/202322h10Business WireAN2 Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
11/05/202322h23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANTXAN2 Therapeutics Inc
11/05/202322h10Business WireAN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
01/05/202313h00Business WireAN2 Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322h26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ANTXAN2 Therapeutics Inc
14/04/202312h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ANTXAN2 Therapeutics Inc
06/04/202323h08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:ANTXAN2 Therapeutics Inc
30/03/202312h08Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ANTXAN2 Therapeutics Inc
29/03/202322h25Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ANTXAN2 Therapeutics Inc
29/03/202322h01Business WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ANTX

Dernières Valeurs Consultées

EU
VK
Vallourec
FTSE
UKX
FTSE 100
EU
ORA
Orange
NASDAQ
NVDA
NVIDIA
EU
PX1
CAC 40
NYSE
JPM
JP Morgan Chase
EU
ACA
Credit Agricole
EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
EU
AI
Air Liquide
NYSE
DIS
Walt Disney
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés